Royce & Associates LP acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 7,127 shares of the company’s stock, valued at approximately $498,000.
A number of other hedge funds have also recently modified their holdings of ZTS. University of Texas Texas AM Investment Management Co. bought a new position in Zoetis in the 2nd quarter worth $25,000. Dunhill Financial LLC lifted its position in Zoetis by 519.3% during the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after purchasing an additional 296 shares in the last quarter. Cassaday & Co Wealth Management LLC bought a new stake in Zoetis during the first quarter valued at about $28,000. First Command Advisory Services Inc. grew its holdings in Zoetis by 3,881.8% during the third quarter. First Command Advisory Services Inc. now owns 438 shares of the company’s stock valued at $31,000 after purchasing an additional 427 shares during the period. Finally, Wellington Grp LLC grew its holdings in Zoetis by 6,675.0% during the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after purchasing an additional 267 shares during the period. Institutional investors own 92.80% of the company’s stock.
Zoetis Stock Performance
Shares of NYSE ZTS opened at $79.09 on Friday. The firm has a fifty day moving average price of $77.16 and a 200-day moving average price of $90.55. The company has a debt-to-equity ratio of 2.51, a current ratio of 2.35 and a quick ratio of 1.40. The stock has a market cap of $32.14 billion, a PE ratio of 12.73, a price-to-earnings-growth ratio of 1.22 and a beta of 0.67. Zoetis Inc. has a 1 year low of $68.77 and a 1 year high of $132.49.
Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $1.75 EPS for the quarter, beating the consensus estimate of $1.51 by $0.24. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The firm had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same period last year, the firm earned $1.70 EPS. The company’s revenue was down 1.3% on a year-over-year basis. Equities analysts anticipate that Zoetis Inc. will post 6.29 earnings per share for the current fiscal year.
Zoetis Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 annualized dividend and a yield of 2.7%. Zoetis’s dividend payout ratio is currently 36.05%.
Zoetis News Summary
Investors following ZTS have been watching these news items:
- Positive Sentiment: The USDA licensed Zoetis’s Poulvac® Procerta® HVT-ND-ILT, a vaccine for chickens targeting three diseases. The approval expands the company’s poultry-health portfolio and could create a commercial opportunity, though the headlines provide no sales or earnings estimates. Article: Zoetis Receives USDA License for Poulvac Procerta HVT-ND-ILT Vaccine for Chickens
- Positive Sentiment: Recent coverage also highlighted news about a dog-allergy treatment and described Zoetis shares as potentially inexpensive. The headline does not provide enough detail to assess the treatment’s likely financial impact. Article: Zoetis Stock Still Looks Cheap Following Fresh Dog Allergy Treatment News
- Neutral Sentiment: Brokerages’ consensus target price is reported at $101.25, while Barclays maintained a Hold rating—signals of potential upside in analyst estimates but also a cautious view from at least one firm. Article: Zoetis Stock Has Consensus Target Price of $101.25 According to Brokerages Article: Barclays Remains a Hold on Zoetis
Wall Street Analysts Forecast Growth
A number of analysts have commented on the company. Jefferies Financial Group upped their price target on Zoetis from $83.00 to $85.00 in a research report on Friday, November 6th. BTIG Research dropped coverage on Zoetis in a research report on Friday, October 30th. They set a “buy” rating and a $200.00 price objective on the stock. Zacks Research raised Zoetis from a “strong sell” rating to a “hold” rating in a research report on Monday, October 26th. BNP Paribas Exane cut their price objective on Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, August 11th. Finally, Morgan Stanley cut their price objective on Zoetis from $85.00 to $82.00 and set an “overweight” rating for the company in a research note on Thursday, October 29th. Eight equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $101.25.
Read Our Latest Research Report on ZTS
Zoetis Company Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Featured Articles
- Five stocks we like better than Zoetis
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
